Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Myeloma.

P Jacobs1

  • 1Department of Haematology, University of Cape Town Leukaemia Centre, Groote Schuur Hospital, Observatory, South Africa.

Disease-A-Month : DM
|June 1, 1990
PubMed
Summary
This summary is machine-generated.

Multiple myeloma is a plasma cell cancer with varied symptoms and potential for organ damage. Effective treatments significantly prolong survival, offering promising management options for patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nitric oxide expression in the spleen, but not in the liver, correlates with resistance to blood-stage malaria in mice.

Journal of immunology (Baltimore, Md. : 1950)·1995
Same author

Blunted erythropoietin response to anaemia in tuberculosis.

European journal of haematology·1995
Same author

Immune response of mice infected with Schistosoma mansoni is modulated by antifibrotic treatment.

Annals of tropical medicine and parasitology·1995
Same author

Bone marrow failure. Pathophysiology and management.

The Central African journal of medicine·1995
Same author

A comparison of intensive care unit utilization in Alberta and western Massachusetts.

Critical care medicine·1995
Same author

Role of macrophage-derived nitric oxide in suppression of lymphocyte proliferation during blood-stage malaria.

Journal of leukocyte biology·1995
Same journal

GLP-1 agonist and neuroprotection in Stroke and Parkinson's disease: A systematic review.

Disease-a-month : DM·2026
Same journal

GLP-1 receptor agonists for weight management and potential thromboembolic risk reduction in high risk population with cancer, diabetes, cardiovascular disease: A systematic review.

Disease-a-month : DM·2026
Same journal

Periodontal disease and diabetic kidney disease: A comprehensive analysis.

Disease-a-month : DM·2026
Same journal

Foreword for Glucagon-like peptide-1 receptor agonists (GLP-1) and its promise for potential benefits.

Disease-a-month : DM·2026
Same journal

Foreword for insulin autoimmune syndrome (Hirata Disease): An updated review of epidemiology, pathophysiology, clinical features, diagnosis, and management.

Disease-a-month : DM·2026
Same journal

Foreword for periodontal disease and diabetic kidney disease: A comprehensive analysis.

Disease-a-month : DM·2026
See all related articles

Area of Science:

  • Hematology
  • Oncology

Background:

  • Multiple myeloma is a malignancy of terminally differentiated B-lymphocytes (plasma cells).
  • Clinical presentation ranges from asymptomatic monoclonal gammopathy to symptomatic disease with skeletal, metabolic, and renal complications.
  • Symptoms can arise from tumor mass (extramedullary plasmacytoma) or systemic effects like hypercalcemia, amyloidosis, and hyperviscosity.

Purpose of the Study:

  • To provide an overview of multiple myeloma, including its clinical spectrum, natural history, and treatment approaches.

Main Methods:

  • The abstract summarizes current knowledge on myeloma diagnosis, pathophysiology, and treatment strategies.
  • It reviews both initial medical management and long-term therapeutic options.

Main Results:

Related Experiment Videos

  • Untreated symptomatic myeloma has a median survival of approximately 7 months.
  • With effective therapy, median survival can be extended to approximately 30 months.
  • Treatment includes chemotherapy (melphalan, prednisone), irradiation, interferon, and high-dose chemoradiotherapy with bone marrow transplantation.

Conclusions:

  • Urgent medical management is crucial for improving renal function and managing acute complications.
  • Specific antitumor therapies significantly improve survival outcomes in multiple myeloma.
  • Advanced treatments like high-dose chemoradiotherapy with bone marrow transplantation offer promising future management options.